PTC Therapeutics Inc.

PTCT | NASDAQ

Price Alert Chart Builder DCF Calculator

$65.26

-$0.11 (-0.17%)

At close: Sep 21, 2026, 4:00 PM ET

$65.40

+$0.14 (+0.21%)

Pre-market: Sep 22, 2026, 5:56 AM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

-0.17%

(1D)

Rating

Updated: Aug 13, 2026

Fundamentals Average

Market Sentiment Bullish

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $5.45B

1D Range

65 66.10

52W Range

57.74 90.87

Valuation (TTM)

PE -112.52

PB -32.94

EV/EBITDA 62.59

Valuation (NTM)

Forward PE 21.76

Forward PEG -1.17

Price Target $105.13

Cash Flow

FCF Yield -1.4%

SBC Adj. FCF Yield -2.9%

SBC Impact -113.4%

Margins

Gross Margin 82.1%

Operating Margin 11.5%

FCF Margin -7.4%

Growth (CAGR)

Revenue 3Y | 5Y 7.2% | 16.4%

Dil EPS 3Y | 5Y 10743.8% | 92.4%

FCF 3Y | 5Y 62.0% | 212.4%

Returns

ROA -1.2%

ROE 21.7%

ROIC 2.6%

Financial Health

Net Cash

$1.53B

Current Ratio 3.39

Interest Coverage 0.63

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

PTC Therapeutics, Inc. (PTCT) is a biopharmaceutical company committed to the research, development, and commercialization of innovative therapies for patients afflicted with rare genetic disorders. I...

Sector Healthcare

Industry Biotechnology

Employees 991

IPO Date Jun 19, 2013

Website www.ptcbio.com

Fiscal Year January - December

Full Company Profile

Latest News

6 days ago · seekingalpha.com

PTC Therapeutics, Inc. (PTCT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

7 days ago · defenseworld.net

California State Teachers Retirement System Has $543.82 Million Stock Position in PTC Therapeutics, Inc. $PTCT

California State Teachers Retirement System raised its stake in shares of PTC Therapeutics, Inc. (NASDAQ: PTCT) by 7,806.7% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,666,961 shares of the biopharmaceutical company's stock after buying

1 month ago · seekingalpha.com

PTC Therapeutics, Inc. (PTCT) Discusses Acquisition of ST-920 Fabry Gene Therapy Asset and Clinical Data from STAAR Study Transcript

2 months ago · zacks.com

PTC Therapeutics (PTCT) Loses 20.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

PTC Therapeutics (PTCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

2 months ago · zacks.com

PTC Therapeutics (PTCT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for PTC Therapeutics (PTCT) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

2 months ago · seekingalpha.com

PTC Therapeutics, Inc. (PTCT) Q2 2026 Earnings Call Transcript

2 months ago · zacks.com

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics (PTCT) came out with quarterly earnings of $0.92 per share, beating the Zacks Consensus Estimate of a loss of $0.17 per share. This compares to a loss of $0.83 per share a year ago.

3 months ago · zacks.com

PTC Therapeutics (PTCT) Upgraded to Strong Buy: Here's What You Should Know

PTC Therapeutics (PTCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

3 months ago · zacks.com

PTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?

PTC Therapeutics (PTCT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.